Pediatric patients with stage iv rhabdomyosarcoma significantly benefit from long-term maintenance therapy: results of the cws-iv 2002 and the cws dok iv 2004-trials

HIGHLIGHTS

• who: Lars Tramsen and colleagues from the Department of Pediatrics, University Schleswig-Holstein, Campus Kiel, Kiel, Germany have published the Article: Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials, in the Journal: (JOURNAL)
• what: The authors report prognostic factors and outcome of patients receiving multimodal treatment for RMS followed by either LTMT, HDCT, or alloHSCT. The aim of the window trial was to evaluate response and toxicity of this combination compared to monotherapeutic topotecan therapies published before . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.